Home › Research › Inflammation and the immune system
Plasma biomarkers of amyloid, tau & neuroinflammation in Alzheimer’s disease and corticobasal syndrome
Carolin Kurz, Laura De Carli, Selim Üstün Gürsel, Isabelle Schrurs, Alexander Jethwa, Margherita Carboni, Tobias Bittner, Sayuri Hortsch et al.. European Archives of Psychiatry and Clinical Neuroscience, 2025-05-02
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
In AD cases, pTau181 and ApoE4 levels were elevated, and the Aβ1-42/1-40 ratio was reduced. ROC analysis showed high accuracy for pTau181, ApoE4 and Aβ1-42/1-40 in discriminating AD from HC, with a combination significantly improving performance. However, limited fold change, and high variability reduced the diagnostic applicability of Aβ1-42/1-40 ratio. Elevated NfL levels were the most reliable biomarker for CBS-Aβ(-) cases. GFAP showed limited discriminatory power due to overlapping levels, suggesting that it may not serve as a disease-specific biomarker but may be indicative of general neurodegeneration. This study highlights the diagnostic utility of pTau181, ApoE4 and the Aβ1-42/1-40 ratio for AD and NfL in the CBS-Aβ(-) cases and emphasizes the added value of combined biomarker models for group differentiation. Prospective studies will help validate these findings and refine clinical thresholds.
What this study adds
Evidence grade: Low
The record lists 27 participants. This study found that blood levels of pTau181 and ApoE4 were elevated and the Aβ1-42/1-40 ratio was reduced in Alzheimer's disease, and that combining markers improved distinguishing Alzheimer's from healthy controls. These are diagnostic findings only and say nothing about treating, curing, or preventing the disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Kurz, C., De Carli, L., Gürsel, S. Ü., Schrurs, I., Jethwa, A., Carboni, M., et al. (2025). Plasma biomarkers of amyloid, tau & neuroinflammation in Alzheimer’s disease and corticobasal syndrome. European Archives of Psychiatry and Clinical Neuroscience. https://doi.org/10.1007/s00406-025-02013-z
Vancouver
Kurz C, De Carli L, Gürsel SÜ, Schrurs I, Jethwa A, Carboni M, et al. Plasma biomarkers of amyloid, tau & neuroinflammation in Alzheimer’s disease and corticobasal syndrome. European Archives of Psychiatry and Clinical Neuroscience. 2025. doi:10.1007/s00406-025-02013-z. PMID: 40314736.
BibTeX
@article{kurz2025-40314736,
author = {Kurz, Carolin and De Carli, Laura and Gürsel, Selim Üstün and Schrurs, Isabelle and Jethwa, Alexander and Carboni, Margherita and Bittner, Tobias and Hortsch, Sayuri and others},
title = {{Plasma biomarkers of amyloid, tau \& neuroinflammation in Alzheimer’s disease and corticobasal syndrome}},
journal = {European Archives of Psychiatry and Clinical Neuroscience},
year = {2025},
doi = {10.1007/s00406-025-02013-z},
pmid = {40314736},
url = {https://doi.org/10.1007/s00406-025-02013-z}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- In AD cases, pTau181 and ApoE4 levels were elevated, and the Aβ1-42/1-40 ratio was reduced.
- ROC analysis showed high accuracy for pTau181, ApoE4 and Aβ1-42/1-40 in discriminating AD from HC, with a combination significantly improving performance.
- However, limited fold change, and high variability reduced the diagnostic applicability of Aβ1-42/1-40 ratio.
- Elevated NfL levels were the most reliable biomarker for CBS-Aβ(-) cases.
- GFAP showed limited discriminatory power due to overlapping levels, suggesting that it may not serve as a disease-specific biomarker but may be indicative of general neurodegeneration.
Why it matters
This study found that blood levels of pTau181 and ApoE4 were elevated and the Aβ1-42/1-40 ratio was reduced in Alzheimer's disease, and that combining markers improved distinguishing Alzheimer's from healthy controls. These are diagnostic findings only and say nothing about treating, curing, or preventing the disease.
Study details
- Participants27
- Evidence strengthLow
How this study scored 49/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (European Archives of Psychiatry and Clinical Neuroscience) |
| Journal's citation record | 2 / 4 | European Archives of Psychiatry and Clinical Neuroscience: journal h-index 158 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 27 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 13 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 4.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 4 / 6 | Cited 8.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 13 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Robert Perneczky: h-index 73 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Imperial College London: institution h-index 1,744 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 11 institution(s) in 4 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40314736) |
| Free to read | 2 / 2 | Free to read |
| Total | 49 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1007/s00406-025-02013-z
- PubMed: 40314736
- Original source →
- Free full text: European Archives of Psychiatry and Clinical Neuroscience →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 22.
Related studies in Inflammation and the immune system from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.